Detalles de la búsqueda
1.
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
Breast Cancer Res Treat
; 203(3): 497-509, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37938495
2.
Essential medicines list in national cancer control plans: a secondary analysis from a global study.
Lancet Oncol
; 23(3): e144-154, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35240089
3.
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
Lancet Oncol
; 23(10): 1274-1286, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36108662
4.
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.
Br J Cancer
; 127(10): 1799-1807, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36050448
5.
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort.
Mod Pathol
; 33(5): 792-801, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31740722
6.
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
J Transl Med
; 17(1): 391, 2019 11 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-31771601
7.
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.
BMC Cancer
; 14: 515, 2014 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25026897
8.
Phase II design with sequential testing of hypotheses within each stage.
J Biopharm Stat
; 24(4): 768-84, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24697358
9.
Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting.
JCO Precis Oncol
; 8: e2300334, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38271655
10.
Randomized phase II selection trial of FLASH and conventional radiotherapy for patients with localized cutaneous squamous cell carcinoma or basal cell carcinoma: A study protocol.
Clin Transl Radiat Oncol
; 45: 100743, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38362466
11.
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma.
Sci Immunol
; 9(92): eadg7995, 2024 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38306416
12.
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
BMC Cancer
; 13: 163, 2013 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-23537287
13.
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.
Lung Cancer
; 175: 141-151, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36535121
14.
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Nat Cancer
; 4(10): 1410-1417, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37735588
15.
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
J Immunother Cancer
; 11(10)2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37880184
16.
European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
J Thorac Oncol
; 18(9): 1233-1247, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37356802
17.
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Breast Cancer Res Treat
; 132(2): 609-19, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22187126
18.
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Lancet Oncol
; 12(3): 236-44, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21354370
19.
Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort.
Lung Cancer
; 174: 27-35, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36283211
20.
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Lung Cancer
; 169: 77-83, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35660972